A call for innovators’ dreams to come true
Welcome (young) friends— to the University Innovation Cluster
Some of you must have already heard about the University Innovation Cluster—a joint effort by Biotechnology Innovation Research Assistance Council (BIRAC) and the National Innovation Council (NIC). The launch was a very collegial event. People are central to the development of science and technology and any opportunity to nurture bright new ideas of young scientists is welcome.
These clusters will be a boost to those bright potential entrepreneurs waiting for an environment which allow them to try out their ideas for start-ups and perhaps address problems in which biotech can be part of the solution. It could be transformative.
Mr Sam Pitroda in his statement rightly said that India needs to increase government investment in biotechnology. The success of the new innovation clusters can help biotechnology play what many expect to be a central role in economic growth and ‘social innovation’.
As of now BIRAC, a Public Sector arm of the DBT, has partnered with the NIC to announce only five universities as part of the cluster, but the plan is to scale it up very soon to over twenty five.
the UIC will be hosted in five universities to nurture a culture of applied research and need oriented innovation among researchers in universities
Under this initiative, the Cluster Innovation Centre in Biotechnology will be hosted in five universities selected for the purpose to nurture a culture of applied research and need oriented (societal or industry) innovation among researchers in universities.
The first five are the Anna University, Chennai; Panjab University, Chandigarh; Tamil Nadu Agricultural University, Coimbatore; University of Rajasthan, Jaipur and the University of Agricultural Sciences, Dharwad.
The government will provide a total of Rs. 1.5 to 2 crore (15 to 20 million) per fellow per university to develop the innovation laboratories in these universities and nurture fellows to work on their ideas for three years mentored by researchers in the field.
The Cluster Innovation Centre will be the nerve centre to manage the University Innovation Cluster activities. Along with facilitating the creation of networks, partnerships between stakeholders to strengthen the innovation ecosystem, the CIC-B is also envisaged to provide pre-incubation support to innovative ideas and to innovators for effective translation into products thereof. Such support will include technical trainings, IP management, technology business management and access to risk finance, among others.
All programmes currently operated by BIRAC will be accessible through the UIC initiative and participant universities will be encouraged to creatively leverage existing programmes for maximum gain. The programme would also aim at leveraging existing resources from complementary private and public support programmes and institutions.
An open invitation was sent out to universities to show interest in participating in this initiative. Judging by the potential for success and enthusiasm to take the initiative forward, the abovementioned five universities have been selected to participate in Phase-I of this initiative.
These universities will shortly set up CIC-Bs and will initiate innovation-focused activities in the near future. With enthusiastic support promised by all stakeholders of the biotech sector, this initiative is envisaged to start showing positive results as early as the end of the year.
We want to see your ideas grow into our own business. So we are happy to mentor you for three years under a stalwart in your area of thought. Welcome all… please apply for the national competition for fellowships, which will be announced soon to see your ideas fructify.
A new multi-institutional programme study on pre-term births
An inter-institutional 5-year project, supported by the DBT, has started and aims to understand the problem so that interventions can be planned
The Department of Biotechnology has just begun a five-year programme of support to address the problem of pre-term births, which causes around 300,000 neo-natal deaths in India annually.
The aim of the programme is to understand the disease biology and characterise pre-term birth on the basis of its causes.
The final goal for the Rs 48.85 crore (Rs 4.8 billion), inter-institutional programme which involves multidisciplinary research effort is to predict and diagnose pre-term birth (PTB).
This will help plan intervention methods and develop therapeutic agents against this scourge.
The DBT says in a recent statement: “It is expected that the clinically relevant research outputs from the study will aid characterisation of the biological, clinical and epidemiological risk factors to help assess whether a mother is under high or low risk of delivering before term (achieve appropriate risk stratification of mothers).
“These in turn would provide a basis for discovery of novel therapeutic agents and determine appropriate timing for their clinical application.”
the basic aim
is to understand the disease biology
of PTB and understand its causes.
The basic aim of the project is to understand the epidemiology of PTB, its genetic and environmental interactions, and changes in vaginal microbial landscape.
The programme highlights include development and evaluation of putative bio-markers, identification of simple microbiological tool-based vaginal risk factors, modulation of vaginal microbiota for therapeutic purposes and evaluation of environmental modification chosen from SNP analysis.
A metagenomic approach for profiling of vaginal microbial flora would be taken up and this information will be correlated with PTB, and other dietary and epidemiological risk factors.
“The initial step will be to establish a hospital-based cohort of pregnant women, starting from the first trimester, each of whom will be followed till delivery, explained Dr S Sinha, Advisor Medical Biotechnology division at DBT.
The hospital will be in General Hospital, Gurgaon, in the northern Indian state of Haryana.
The programme will involve clinicians, epidemiologists and biologists from three autonomous institutions of DBT –
Paediatric Biology Centre (PBC), and the Centre for Human Microbial Ecology (CHME) at the Translational Health Science and Technology Institute (THSTI) located at Gurgaon,
Regional Centre for Biotechnology (RCB), also located at Gurgaon and
National Institute of Biomedical Genomics (NIBMG) at Kalyani in the eastern state of West Bengal
The other important partners are the clinicians at the General Hospital Gurgaon and Safdarjung Hospital. Physicians from Maulana Azad Medical College and the All India Institute of Medical Sciences are co-investigators in the programme.
The Wellcome Trust / DBT India Alliance has announced new fellowship opportunities for clinicians and public health researchers in India.
The schemes include two initiatives. One involves a two-year research training fellowship for clinicians. The other includes early intermediate and senior fellowship schemes for clinicians and public health researchers.
The fellowship for clinicians aims to provide them an opportunity to carry out high quality basic and clinical research in a laboratory or clinical environment of their choice.
It is targeted to help medical and allied health professionals who have completed or shall soon complete their master’s degree and are keen on receiving training through high quality research under the supervision of senior scientists with expertise in clinical and basic science research.
Two years personal support will be provided along with research and training costs, an opportunity to get trained in the area of interest, support for joint mentorship under clinical and basic science experts.
A second set of fellowships opportunities have been announced to encourage interested clinicians and public health researchers to pursue their research goals along with their clinical duties.
Among these are early career fellowships that provides unique opportunity for those who have shown promise to pursue a research career and wish to further strengthen their efforts towards achieving a longer term research vision under the guidance of a fellowship supervisor.
Intermediate fellowships are for those who have already built a track record of pursuing clinical or public health research and wish to establish their own research programmes in India. Senior fellowships are for those who have successfully lead an independent research programme and wish to expand that through additional support.
Apart from personal support, the fellowships will provide funds for research support facilities like additional staff and training including international ones.
Of course there are more… I thank the entire community for making this possible.
Amongst the post-colonial countries after the Second World War, India stands out as one of those that have been continuously and significantly investing in science and technology, even through all its crises. This, despite the arguments given by nativists, utopians and dystopians that investing in science and technology is not only useless but also counter-productive. India seems to have recognized that science is a necessary component of all civilizations and a vital partner in sustainable and equitable development. While critical analysis of all science and technologies are always welcome and necessary, we should be careful not to lunge back into dogmatic positions, driven by ideologies and not by evidence.
There are huge differences of opinion about why countries such as India must invest substantially in science. With the country going through a financial crisis, the debate has intensified today. (This article is edited from a recent lecture at the University of Hyderabad by Professor K VijayRaghavan).
More recently, after being conferred the Bharat Ratna, Professor CNR Rao argued for more investment in Indian science. Professor Rao’s take was that it while appreciating that the highest civilian award of the country was given to a scientist, but he wondered aloud about putting more the money where our mouth is… what about chipping in at least two percent of the GDP on science pursuit in a country of 1.2 billion people. The current level is just lower than 1% of GDP and our aim is to invest about 2% of GDP. Of late, we hear the interesting take that half of this 2% should come from industry, similar to the substantial investment by industry in developed economies.
At Hyderabad, I posed the same question: Why should India invest in science? Why should we invest in ‘esoteric’ subjects— pure mathematics, studying the stars and so forth, when so many ‘on-the-ground’ issues like poverty, health, food, etc., confronts us?
Besides, do we not have enough science already? Most of the ‘deep problems’ that we face can be solved by good governance at levels ranging from the civic, the city, the state and country. These important problems are ‘downstream’ issues, far from basic or even new- applied-science. Available knowledge and technologies can solve, most of our problems without new investment in S&T. And, if good science is required can we not borrow it from the best places in the world?
These arguments stem from a deep misunderstanding of what science is and of the role of inventions and novel technologies in a society. Science, and technology too, is far more than the toolbox of instruments to be purchased and used for known tasks.
As with the arts, humanities or music, science is a deep cultural need of all people. A society bereft of scientific thinking and scientific activity is poor. No matter how materially poor we are, we cannot afford to be intellectually poor by having large gaps in our culture. We could do without paintings or music, but we will be a very poor society if we do that. We can dispense with dance, and we can do away with the diversity we have in languages, traditions and cultures and have a uniform society. If we do any or all of these unthinkable things we will be a soulless society. In much the same way, if we do away with science we lose a part of our culture, the natural quest for learning and understanding.
In Hyderabad, a very bright humanities student said, at the end of my talk, that while he saw my point, did I not think that science was a lot more expensive than, say music, to have just this ‘cultural’ justification for its support. True, a radio telescope or the Mars mission or studying the brain is a lot more expensive than encouraging Odissi or BharataNatyam. We do need to calibrate and make sure that we cut our scientific coat according to our cloth.
Technology is the other result of investment in science. In these applications of scientific discoveries, returns are huge and disproportional to investment in basic-science and in engineering-science. India’s space programme, once thought of as a luxury for a developing country has had tremendous economic and cultural consequences. Investing in understanding the immune system and its complexity results in vaccines and drugs. These, in turn, lead to lives saved, to better lives, the result of which is that we can have the time and health to pursue our interests. This results in new scientific frontiers being addressable. In the examples above, the technologies I mention are not ‘copied’ form elsewhere but require considerable inventiveness to apply them in affordable ways.
the elegance of the scientific method
allows us to understand the universe
much better: is this the only universe?
how did it come about?
how did life originate?
How does the brain work?
Opposition to science comes in various shapes and guises. Largely though, I would put them into three categories, Nativist, utopian and dystopian ideologies. The arguments in each case can be quite sophisticated and enamor many and most of us fall into these categories at one time or another.
The nativist view harks back to a Satya- Yug, or a Garden of Eden when everything was fine with the world, when rivers carried honey and humans lived in fragrant, opulent forests. Nativists though choose particular moments in history as their ideal. ‘All was great in ancient India’ or in some other chosen period. There is little evidence for such idyllic times in the past, and if there were such times there’s not too much to be done about it: Unfortunately, time (at least for mere biologists) is unidirectional and will not turn back.
Then, there is the utopian view: Let’s grow all that we need in our back garden, don’t commute to work, live in a commune where everybody is very interactive and very happy… nice world to imagine perhaps, but we have what we have—which is very grim in large parts– and we have to deal with it in a very real way. Such dreams can feed the rich in rich countries, but densely populated large countries don’t have the luxury of utopian solutions today.
The most bullish anti-science argument is the dystopian one: Science messes up everything. It makes bombs, causes blasts, pollutes the environment and so on and so we do not need science. Science, this view argues, is in cahoots with crass commercial calculations of the big market which is taking over our country and the planet, all governments act at their behest, and so forth. Interestingly, the answer to this (wrong) diatribe is to ask for more science and more investment in science. This investment in science if well-connected with our people and our societies and our quests and needs, can be truly transformative. The dystopian views come from the valid concern that science can be distorting when driven solely by market forces. The poor connectivity of scientists and technologists to their societies exacerbates this concern. In trying to stem the advance of the market, the dystopian logic demands stringent and expensive regulatory hurdles. This is counter-productive, as only the big-players can jump through these hoops. If regulation were correct and appropriate, then publicly funded science and technologies can make a prominent presence, in India at least. This can dispel some of the valid concerns in the dystopian argument.
Science has fundamental meaning for all societies. The scientific method is invaluable in every aspect of our lives. Its elegance allows us to understand nature and the universe. Is this the only universe we have, how did it come about, what is the meaning of the stars that we see, how did life originate? How does the brain work? These are some of the questions that intrigue us humans who, naturally curious, search for answers. These answers result in technologies that change our directions and our planet. We realize much more today than ever before that these changes we make must be calibrated to meet our needs and yet sustain our planet. This is feasible through good policies: Science and not dogma and ideology, provides the evidence for these policies.
There is a worldwide perception that in times of crisis, one must invest in doing something useful and at time of plenty one has the time to look at basic research. Interestingly, India has been an exception, as we have invested in basic science even during crisis.
two decades of continued investment
on rotavirus studies has given India
the cheapest vaccine against it,
creating for us a global economic
and diplomatic leadership edge
One example is how the government, its science agencies, in collaboration with the private sector in the country, international agencies and health organisations and scholars worked for two decades from science to translation and developed an inexpensive vaccine against the deadly rotavirus.
This very material outcome of continued investment in science through 20 years of financial, social and political crises of all manners will not just benefit India’s poor, but will help the poor across the world.
Hidden inside such successes is a larger issue. Can India combine science, technology and translation to scale? Can we innovate to do extraordinary science with meager resources? Can we design affordable solutions to our problems?
The rotavirus vaccine saga provides a partial answer. Was there was a ‘top-down’ planning to work on the indigenous rotavirus vaccine? Not really. The vaccine came about through passion, chance, grit… the details of which have been outlined elsewhere.
The Indian government, all through these years, had kept investing in that project. Scale, then, can come from opportunistic investment in people and their audacious goals. Yet, ‘top-down’ programmes can create an ambience that allows bright and well-trained minds to surface.
Similarly, India has invested in plant biology, genetics, breeding and in food technology. Though the debate has recently been focused on GM issues, the fact remains that without investing in agricultural technology, we cannot address the issues of poverty and food security
Diseases such as malaria, dengue, Japanese encephalitis, lymphatic filariasis, children under five years with stunted growth are a huge burden on India. Preventive and social medicine and a growing economy may address many of these issues well. But science and technology can be transformative here, all the way from the study of these problems revealing new biology as well as providing novel and effective solutions. If we do not delve into these issues, no one else will. And if we do, these and many other areas of study in our environment can provide new challenges in basic biology and well as applications. Studying scientific problems defined from our surroundings as well as the best problems identified anyone in the world can develop an excellent foundation of research in India.
When discussing investment, many ask, for all the money put into science so far, how many Nobel laureates have we created in the last 60 years?
The resources that each science investigator in our best institutions gets in India are quite high. The problem in India is not that we are poorly funding our researchers, but that we don’t fund a large number of researchers. Further, the pipeline that takes funds to our scientists operates in sputters and bursts. We thus need to make our systems hugely more efficient and to also expand the footprint of science. These are the major challenges to overcome if more money is to make an impact.
In the late 19th and early 20th century, science was an individual’s pursuit of passion, J C Bose, C V Raman and, Meghnad Saha are such examples from India. But now, science is a massive institutionalized structure in all large economies. We can no longer rely on random excellence in a huge enterprise, whose centre of mass is in the West and which has with a very large population of excellence.
It is here that we fail in not having a larger and robust strength of scientists who could crowd the wall of excellence. Laurels will be a collateral consequence of having such a cohort. This necessitates more investment as well as a focus on investing this well. As the number of excellent scientists grows to the hundreds and thousands in a country the size of India, a significant number of them will surely be ranked amongst the best in their field globally
Our investment is science today is very modest. To lower this baseline through cuts in difficult times is tempting, but this will be cutting our feet below our knees at a time when there are demanding challenges ahead. This is the message we need to convey to those who control the purse strings, while we set our own house in better order to make dents on difficult problems.
Behind the cheers that hailed the success of the effort, there were funding issues, international collaborations, trust building, hard grind and patience… but in the end what mattered were… the cheers!
Two occurrences—a brilliant young assistant professor at the All India Institute of Medical Sciences spots an interesting viral strain. He meets an equally brilliant scientist from across the Atlantic at a conference in Kolkata. More than two decades of laborious research and India is ready to launch the cheapest Rotavirus vaccine.
A few months ago, when the vaccine was announced, it made headlines. There was cheer, there was pride. One saw the smiling faces of the scientists, officials and the executives behind the endeavor.
Later, there were comments too that if the amount of money that was spent on Rotavac could be given to others, more such products could see the light of day.
Sure enough! That is the ‘can do’ attitude.
With this background, I thought it was relevant to tell the world the story of the inspired pursuance of the dream, the tireless research, the commitment to the goal, the sacrifices, the heartbreaks and the long, patient wait.
It was the early 1980s. Dr MK Bhan was then an assistant professor at India’s premiere medical institute, the All India Institute of Medical Sciences He noticed a strain of rotavirus behaving in a very strange manner. It infected new born babies but the little ones did not develop diarrhoea.
In 1985, Dr Bhan was attending a WHO meeting at Kolkata. There he met Dr. Roger Glass, a diarrhoeal expert working at Centre for Disease Control and Prevention, a laboratory of the National Institute of Health, USA, and intrigued as he was about this strain, discussed it with Dr Glass.
The venue too was an interesting one. Kolkata–where Russian scientist Waldemar Mordecai Wolff Haffkine had worked on the Cholera vaccine and Sir Ronald Ross identified the parasite responsible for malaria. Perhaps such a legacy played a role in fostering another collaboration that would also prove to be historic.
Keen to exchange knowledge, they stated an informal joint research programme. The informal relationship continued for a few years till in 1989-1990, the Department of Biotechnology, Ministry of Science & Technology, Government of India, along with NIH and UNSAID was inspired enough to provide the first funding.
“The scope of the research seemed to be a very bright one and so we decided to fund it,” recalls Dr TS Rao, Senior Advisor at the Department of Biotechnology.
Funding, of course, intensified the activity.
The original team that started work on the neonatal rotavirus infection and its effects comprising of of Dr MK Bhan, Dr Ramesh Kumar, and Dr Nita Bhandari received a boost to increase the pace of their work.
“Dr Bimal Das from the AIIMS, who joined the group subsequently, visited CDC to characterise the strain, which turned out to be a novel assortant of the human rotavirus strain with a single VP4 gene segment replacement of bovine origin,” recalls Dr Glass.
What Dr Glass meant was that when different stains attack the same host sometimes mixing of genetic material of the stains occurs to form a new strain
The strain ‑ now called 116E ‑which had not been seen previously, was characterised as genotype G9P11. Dr Jayashree Ayer, Dr Bhan’s PhD student at AIIMS indicated that after the infection with this strain, the new born’s serum and mucous systems were geared up to build a firewall to any infection of rotavirus.
In parallel, Dr C Durga Rao of the Indian Institute of Science, Bangalore, with Dr Harry Greenberg from Stanford University, also started working on another similarly promising strain of rotavirus called I321.
For more than two decades, the two independent research teams worked in parallel under the auspices of the Indo-US Vaccine Action Program (VAP), a bilateral programme implemented since 1987 by DBT and NIAID/NIH, to study the two different naturally occurring, weakened strains and develop new rotavirus vaccines for infants.
NIH contracted with DynCorp to produce clinical-grade pilot lots of the vaccines in 1997 and evaluate those lots in American adults and children prior to shipping them to India. In 1998, VAP solicited commercial partners in India for the next stage of development and identified Bharat Biotech International Ltd., a Hyderabad-based vaccine manufacturing company, to develop both vaccine candidates.
In 2000, a consortium of partners including Bharat Biotech, CDC, NIH, AIIMS, StanfordUniversity, and IISc, submitted a proposal to PATH and DBT for support to move the two vaccine candidates through production, testing, and surveillance. Through the Bill & Melinda Gates Foundation-funded Children’s Vaccine Program, PATH joined the collaborative effort in 2001.
Thus was formed a unique group committed to social innovation and inspired to reach vaccine to the suffering people at an affordable price.
In 2003, Bharat Biotech convened the various partners to discuss the clinical development plan for the 116E and I321 vaccine lots. Trials conducted in 2005 showed that while both of them were safe, 116E provided significantly better protection to the disease.
Each of the partners played a very important role.
According to Nita Bhandari, a Public Health Researcher who coordinated the clinical trials and the multi-investigator, multi-agency programme, described it as a challenging task as was building trust among them and maintaining it for a long period. “We had to learn continuously and execute brilliantly, over a long period of time” she pointed out.
The sharing of the costs of development between several partners played a crucial role in limiting the price of the vaccine to just $1 per dose.
Bharat Biotech says that highly efficient manufacturing process and innovative product development efforts also contributed to keeping the costs low.
The other mandatory trials and permissions and other procedures for drug development took about a decade more and we came out with what is a truly Indian vaccine—the strain was an Indian one, so was the company a brave young one with a dynamic CEO with a never say die attitude and, of course, the trials which involved scores of Indians.
The international collaboration in this vaccine is not to be underestimated and the best and the brightest in the vaccine field came together for this vaccine which, hopefully, can be used the world over.
Wishing you all a merry Christmas and a very happy new year
My New Year promise to you is more engagement through this blog and lots of such good news from DBT !
PS: We have a new communication team that is now in place: The Editor-in-Chief and her team will be writing most of these blogs (As is the one above). When I write one myself, I will specifically sign off. Of course, responsibility for what is written is with me
All the best for 2014, and better and more communication from us in 2014
A few years ago the Indian Railways launched the ‘bio-toilets’ scheme to ensure faeces-free tracks and make its trains less smelly. At present, it is running 1,400 coaches with 3,800 bio-toilets in various trains, and plans to boost the effort by covering more trains this year—a great relief indeed for the huge populace that this mode of transport ferries across the country.
Healthy toilets are the necessity of the hour and India needs more such new ideas in its basket to pick and chose the right one.
Open defecation and poor sanitation are India’s shame. Both in rural and urban areas, a major portion of our population either defecate in the open or simply store their waste, with no sustainable way to handle it once their on-site storages—such as a septic tanks or latrine pits—fill up.
We need innovative solutions that will suit the people, be affordable, environment friendly, sustainable, water saving and manageable. We need technologies to empty toilets before they pile up to a level that can affect people’s health, life and property.
Forty per cent of the world’s population—2.5 billion people—practice open defecation or lack adequate sanitation facilities, and the consequences can be devastating for human health as well as the environment.
Even in urban areas, where household and communal toilets are more prevalent, 2.1 billion people use toilets connected to septic tanks that are not safely emptied, or use other systems that discharge raw sewage into open drains or surface waters.
In India, although around 275 million people gained access to improved sanitation between 1990 and 2011, 615 million still defecated in the open in 2011 (WHO and UNICEF 2013) and millions of tonnes of faecal sludge collected from pit latrines and septic tanks are discharged untreated into the environment, creating an important health hazard.
Solving this problem requires researchers committed to take up this challenge. They also need support to dedicate themselves to bring about innovative solutions. Responding to this need, we have called for proposals from those who think on these lines.
Our aim is to support talented researchers to conceptualise prototype and field-test highly innovative ways to process human waste for sanitation service delivery.
This is the first programme under the Memorandum of Understanding between the Bill & Melinda Gates Foundation (BMGF) and the Department of Biotechnology (DBT), signed last year, to collaborate on mission-directed research to support health research and innovation.
It aspires to boost to the government’s Nirmal Bharat programme, with dreams of a clean and healthy nation that thrives and contributes to the well being of our people and the habit of open defecation is entirely eliminated.
We hope to attract innovative new ideas as well as build on some great efforts that have taken place.
For example, IIT-Kanpur has developed a cheaper “zero-discharge” toilet that will separate 90 per cent of the liquid from the waste and reuse it for flushing.
The DRDO has also developed a novel bio-toilet technology. The brave and determined in the Central and State Governments, as well as several dedicated NGOs are addressing this problem and have been doing so for a while.
It is due to their efforts that we have at last some levels of sanitation in place and are perhaps inching ahead and not slipping back.
It’s all very well for all us to point to the problem. Yet, the scale and complexity of the problem seems to defy an easy or comprehensive solution.
When asked to suggest one, most scientists will say that science and technology have no substantive role here and the problems and their solutions lie in the realm of sociology and economics.
Indeed, many might say that the technologies for toilets already exist and all we need to do is to implement them. Real life is a lot more complex.
Effective solutions emerge from a barrage of ideas. They will also have to be scalable and they need to be designed, prototyped and field- tested. Finally, they must be attractive to entrepreneurs and industry and attractive (yes!) to users.
We are eagerly looking forward for some zany ideas from talented young researchers to see the light of day!
Read on about the call for proposals from the DBT, BIRAC and the Bill and Melinda Gates Foundation and take a look at the attached advertisement. And do apply! Let’s work together to clean up and better all our lives. Gandhi Jayanti is a great day to start.
Links to help your application
We step aside from our journey through the endeavours of our scientists working in different DBT institutes, to serve up some good news on our international collaborations.
The Department of Science and Technology (DST) and the Department of Biotechnology (DBT) have signed separate Memoranda of Understanding (MoU) with RIKEN, Japan’s largest comprehensive research institution renowned for high-quality research in a diverse range of scientific disciplines.
The aim is to launch joint research programmes in the fields of biology, life sciences and material sciences.
Nobel Laureate scientist Professor Ryoji Noyori signed the MoU in New Delhi on September 14 as the President of RIKEN.
Genome related research ‑ including systems biology, development of bioinformatics tools, detection tools such as spectroscopy ‑ would be some of the areas the research programmes under this MoU would be focusing on.
For us at DBT, this MoU will usher in a new era of cooperation in the area of innovations and techniques for the agricultural and pharmacological industries in India.
You may be wondering how long the MoU would take to fructify. It is perhaps natural to ask: “Is this yet another formality being trumpeted?” Such processes do take some time, though.
But the signing of the MoU will be followed very promptly by an agreement for joint laboratories for research on materials and biological sciences.
The function held on September 14 comes from years of interaction that have resulted in close interactions and institutional as well as country-wise bonds of friendship.
So, this is a formal step based on a strong foundation.
The laboratory on materials sciences would be a collaboration between Jawaharlal Nehru Centre for Advanced Scientific Research, the Indian Institute of Science (IISc )and RIKEN and will be funded by the DST.
The laboratory on neurosciences and developmental biology is collaboration between the National Centre for Biological Science (NCBS/TIFR), the Institute for Stem Biology and Regenerative Medicine (INSTEM) and RIKEN Center for Cell and Developmental Biology, and will be funded by the DBT.
Our soon-to-be spruced-up and ‘happening’ website will keep you all posted about such happy tidings.
Under the RIKEN-DBT & DST joint research initiative, RIKEN and DBT or DST will determine the fields of collaboration, selection methods and numbers of collaborative programmes through mutual collaboration.
Apart from joint research programmes, the joint initiative will also support exchange of researchers, post-doctoral fellows and knowledge exchanges through seminars and symposia.
In a public lecture at the National Institute of Immunology to celebrate the signing of the MoU Professor Ryoji Noyori highlighted the importance of scientific collaborations in reaching the benefits of science to the people at large.
The hall was packed with students from the research colleges of the Delhi University and from neighbouring institutes.
Elaborating on his own research on asymmetric catalysis and how he applied it on catalytic hydrogenation, Professor Noyori emphasised that while serendipity is important in scientific discoveries, the young should know that chance only favours the prepared mind.
And mere school education is not sufficient to be prepared, in terms of science, he said.
He greatly appreciated India’s successes, especially in mathematics, and in facilitating mass access to medicines by producing low cost generic options.
Earlier collaborations with RIKEN have been quite productive.
We in DBT look forward to facilitate more such collaborations to encourage diversity of ideas in science that can trigger better solutions.
We start a new series on scientists and their teams to understand not just a specific success, such as a product or publication, but how the team works on a problem, who they are and how they have dedicatedly kept the ship on course.
Salmonella–a bacterium, the same strain of which produces different diseases in different hosts, and closely related serotypes behave in starkly varied manners.
For example, Salmomella typhi is the culprit behind the life-threatening typhoid fever rampant in Africa, Asia and South America.
However, another serotype, Salmonella typhimurium, produces self-limiting localised gastroenteritis with infection restricted to the gut.
Again, the symptoms characterising the intrusion of the serotype into the body of mice starkly differ from those seen in the human body.
In mice, Salmonella typhimurium leads to a systemic disease that is analogous to human typhoid while S. typhi does not establish successful infection.
Vaccines developed against S. typhi have not resulted in lasting defence against this pathogen.
The reasons remain largely elusive. The unique behaviour of this pathogen intrigued Ayub Qadri and his team at the National Institute of Immunology (NII), New Delhi.
The Hybridoma Lab headed by Qadri has been probing the reasons for different clinical outcomes produced by these two closely related Salmonella serotypes and the mechanisms by which pathogenic Salmonella modulates the hosts’ immune defences in order to establish systemic infection.
Their aim is to understand interactions of the immune system with these closely related Salmonella serotypes, which could provide guidelines for designing a more effective vaccine – one of the areas of interest for us at the DBT and other agencies.
The Hybridoma Lab’s latest discovery is that T cells, which are primarily involved in adaptive immunity, might also contribute to innate immune responses.
Their findings also suggest that innate immune responses during microbial infections may be regulated by host lipids.
This is an important finding, and we are all keenly awaiting their further work on how these lipids may be participating in modulating innate immunity.
However, this was not a one off find. I would like to run you through the team’s relentless probe into the behaviour of Salmonella serotypes and their long journey to understand the tricky interplay between this pathogen and the host.
When Qadri started working on Salmonella typhi, any vaccine against this pathogen had not come to the market, and timely detection of the infection was very difficult.
Determined to improve this situation, he initiated an independent research programme to understand host-microbe interactions during infection by this pathogen.
In a significant finding in 2004, Qadri, with his student Amita Sharma, found that a protein called prohibitin might be engaged by S. typhi to modulate the immune system when this bacterium attacks the host (published in PNAS).
In another significant contribution a few years later, his group found that host cells produce a lipid that ‘tricks’ Salmonella into secreting flagellin ( a key bacterial molecule that generates inflammatory and innate immune responses) so that the bugs can be detected by the host sensor, triggering an immune response.
This novel finding of Ayub Qadri and Naeha Subramanium was published in Nature Immunology in 2006.
Following up on this work, Qadri’s team has now found that the ‘trick’ is detected by the bug soon after it is started and production of flagellin is stopped.
They are trying to understand the ‘trick’ so that the flagellin production can be prolonged.
In 2010, they registered another important find — that haemoglobin might be able to neutralise the anti-immune capability of Vi polysaccharide (outer coating of S. typhi responsible for its virulence; also Salmonella vaccine) and transform it into an immune activator.
They are now working on understanding how this pro-inflammatory capability of Vi might be contributing to the vaccine’s efficacy.
Led by an efficient captain, the members of his team are equally passionate. While Ajay Suresh Akhade is assessing the regulation of TLR responses, Farhat Parveen is trying to investigate the role of membrane prohibitin in cell signaling.
Sonia is probing deeper into the differences between S. typhi and S. typhimurium, and Jitender Yadav is restless to understand the modulation of the immune responses by pathogenic Salmonella.
The teams’ collective work will significantly contribute to understanding and exploiting the mechanisms of the immune system, using various tools of modern biology to pursue creative solutions to a broad range of health problems.
With inputs from science journalist Archita Bhatta
Here is a link to a must read not so recent paper, in Nature, on the global prevalence of dengue. One of the authors is Jeremy Farrar who will soon take charge as Director of the Wellcome Trust. Farrar has done stellar research in tropical diseases in the Trust’s labs in Vietnam.
Here is the abstract of the article published in Nature. Note the last sentence. The DBT has programs and support in dengue research working on those lines. The Abstract: “Dengue is a systemic viral infection transmitted between humans by Aedes mosquitoes. For some patients, dengue is a life-threatening illness. There are currently no licensed vaccines or specific therapeutics, and substantial vector control efforts have not stopped its rapid emergence and global spread. The contemporary worldwide distribution of the risk of dengue virus infections and its public health burden are poorly known. Here we undertake an exhaustive assembly of known records of dengue occurrence worldwide, and use a formal modelling framework to map the global distribution of dengue risk. We then pair the resulting risk map with detailed longitudinal information from dengue cohort studies and population surfaces to infer the public health burden of dengue in 2010. We predict dengue to be ubiquitous throughout the tropics, with local spatial variations in risk influenced strongly by rainfall, temperature and the degree of urbanization. Using cartographic approaches, we estimate there to be 390 million (95% credible interval 284–528) dengue infections per year, of which 96 million (67–136) manifest apparently (any level of disease severity). This infection total is more than three times the dengue burden estimate of the World Health Organization. Stratification of our estimates by country allows comparison with national dengue reporting, after taking into account the probability of an apparent infection being formally reported. The most notable differences are discussed. These new risk maps and infection estimates provide novel insights into the global, regional and national public health burden imposed by dengue. We anticipate that they will provide a starting point for a wider discussion about the global impact of this disease and will help to guide improvements in disease control strategies using vaccine, drug and vector control methods, and in their economic evaluation.”
And, below is news of a practical dengue detection kit from the ICGEB, New Delhi. The text is from Professor Virander Chauhan, Director ICGEB Delhi. The ICGEB, amongst other places, is involved in a Dengue vaccine initiative. The one at ICGEB is led by Navin Khanna.
A Day 1 Dengue Detection Kit
Co-developed by J. Mitra& Co. and ICGEB New Delhi
Dengue disease may be asymptomatic or manifest symptoms ranging from mild fever to severe hemorrhage and shock syndrome, making clinical diagnosis difficult. Hence, a lot of emphasis is being made on the development of laboratory diagnostic methods which could enable quick and accurate detection of dengue. Timely diagnosis of this disease may prevent its progression to severe hemorrhagic conditions and death. Laboratory diagnosis of dengue may be based on isolation of virus, detection of viral genome, viral antigens or dengue-specific antibodies.
Currently, a number of kits are commercially available for the diagnosis of dengue on the basis of detection of IgG, IgM and NS1 antigen, either alone or in combination, using rapid tests (based on immune-chromatography) or ELISAs. Panbio Limited, Standard Diagnostics and BioRad have been the major players involved in the development of these kits.
An Indian company J. Mitra & Co Pvt. Ltd. in collaboration with International Center for Genetic Engineering and Biotechnology (ICGEB), New Delhi, has developed a test for the simultaneous detection of Dengue NS1 antigen and dengue IgM/IgG antibodies in human plasma/serum. This unique 3×1 combo rapid test provides a wider window of detection for dengue infection. This is very useful for the Indian settings where both primary and secondary dengue infections are co-prevalent. Further, the uniquely designed NS1 binder and reveal reagents used in the Dengue Day 1 test are highly cross-reactive between all 4 dengue virus serotypes, enabling detection of dengue infections irrespective of its serotype.
Dengue Day 1 Test is a rapid solid phase immuno-chromatographic test for the qualitative detection of Dengue NS1 Antigen and differential detection of IgM and IgG antibodies to Dengue virus in Human serum/plasma. This test is for in vitro diagnostic use only and is intended as an aid in the earlier diagnosis of Dengue infection & presumptive diagnosis between primary and secondary Dengue infection.
Dengue Day 1 test kit consists of two devices: one device for detection of Dengue NS1 antigen and second device for the differential detection of Dengue IgM/IgG antibodies in Human serum/plasma.
Dengue NS1 Antigen device contains two lines; ‘C’ (Control line) & “T” (Dengue NS1 Antigen test line). Test line is coated with anti-dengue NS1 Ag. When a sample is added to the device, Dengue NS1 antigen if present in the sample will bind to the anti-dengue NS1 gold colloidal conjugate making antigen antibodies complex. This complex migrates along the membrane to the test region and forms the visible pink line at “T” as antibody-antigen-antibody gold colloid forms.
Dengue IgM/IgG test device contains three lines; “C” (Control line), “M”(IgM test line) & “G”(IgG test line).IgM test line is coated with anti-human IgM and IgG test line is coated with anti-human IgG. When a sample is added to the device, IgG and IgM antibodies in the sample react with anti-human IgM or IgG antibodies coated on the membrane respectively. Colloidal gold complexes containing dengue 1-4 antigens is captured by the bound anti-dengue IgM or IgG on respective test bands located in the test window causing a pale to dark red band to form at the IgG or IgM region of the test device window.
First line testing kit for detecting dengue infection from day 1 using NS1 Antigen & differential detection of IgM&IgG Antibodies.
Diagnosis of both Primary & Secondary Infection.
Detects all 4 serotypes of Dengue virus.
Highly Sensitive & Highly Specific.
Long shelf life: 18 months at 2-30°C.
Convenient pack sizes: 10 Tests & 25 Tests.
Being sold in >40 countries in Asia and Africa.
Variability in vaccine efficacy
Natural selection in a Bangladeshi Population from the cholera-endemic Ganges-river delta: Two independent questions with similar answers from two studies.
Currently available vaccines against various infections do not elicit similar levels of immune response in individuals receiving them. In a study on a cholera vaccine, Partho Majumder and his colleagues have found genetic variants that are associated with immune response. Interestingly, this study also found an innate immunity gene to be associated with vaccine response. Their study will soon be published in the European Journal of Human Genetics, but is already available online here on the journal’s web site.
Partho Mazumder is a leading human geneticist who heads the National Institute of Biomedical Genomics. We discussed a recent news item in The Hindu, by email. Here’s the original article in Science Translational Medicine . Here’s what Partha has to say on this important paper:
Partho says: “Till a few years ago, diseases were classified as being due to two separate sets of causes, genetic and environmental. Infectious diseases were provided as examples of “environmental diseases.” With the ability to carry out genetic studies spanning the entire human genome, it has become clear that genetic variations in the host modulate susceptibility to infectious diseases. This paper on cholera-susceptibility is an excellent example. This paper is interesting not only because of its significant conclusions pertaining to susceptibility to a deadly infectious agent, Vibrio cholerae, but also because of its innovative use of population genetic and statistical methods. The investigators reasoned that individuals who had the genetic ability to escape the attacks of Vibrio cholerae in spite of living in a cholera-endemic region must have gained a selective advantage. Therefore, if one is able to identify the regions of the genome that confer such selective advantage in a cholera-endemic region – such as, Bangladesh, it may be possible to identify genes that confer resistance to cholera. The authors did just this; they first identified genomic regions that have evolved under strong selective pressures, then they identified some variants in genes and genetic pathways that were associated with resistance to cholera, which they validated in an independent sample. They found that variants in the innate immune signaling pathways, which are responsible for recognizing the pathogen, are primarily associated with cholera-resistance. Some other genes that are highly expressed in the digestive tract were also found to be associated with resistance.
Understanding biological mechanisms underlying resistance to infectious diseases are a key to vaccine development. The findings of this study are a major step in that direction.”
Here’s great news, live from the Rotavirus meeting at Delhi. A terrific example of collaboration and staying power for an important cause: Reducing childhood mortality due to diarrhoea.
Nita Bhandari talks about her team. This is hot off the press and more details in due course.
Dr. Nita Bhandari
Society for Applied Studies
Rotavirus Vaccine Developed in India Is a Major Breakthrough
Today we celebrate a wonderful breakthrough for Indian researchers, but most importantly for India’s children. Each year, over 1 lakh Indian children die from the most common and severe cause of diarrhoea: rotavirus.
I was thrilled to be part of history today as we announced positive results from a clinical study of the first indigenous rotavirus vaccine. This rotavirus vaccine was developed from an Indian strain by an Indian company, and tested by Indian investigators in an effort led by the Indian government and supported by several national and global partners.
The rotavirus vaccine we studied (ROTAVAC®) significantly reduced severe rotavirus diarrhoea by more than half—56 percent during the first year of life, with protection continuing into the second year of life. Moreover, the vaccine also showed impact against severe diarrhoea of any cause. The clinical results indicate that the vaccine, if licensed, could save the lives of thousands of children each year in India.
I am proud to have led an extraordinary team of clinical investigators at three sites across India for this pivotal clinical study—the Centre for Health Research and Development, Society for Applied Studies (CHRD-SAS) in New Delhi; Shirdi Sai Baba Rural Hospital, KEM Hospital Research Centre in Vadu, Pune; and Christian Medical College (CMC) in Vellore. The Principal Investigators were Dr Temsunaro Rongsen-Chandola at CHRD-SAS, Dr Ashish Bavdekar at KEM, and Dr Gagandeep Kang at CMC. I was supported by Kalpana Antony and Sunita Taneja.
The experience, expertise, and excellence of the investigators ensured that this trial met the highest standards for ethics and patient care and complied with international standards for good clinical practices. In particular, we had in place a strong safety net to identify and treat illnesses, especially gastroenteritis, among study infants as early as possible. We gave mobile phones to the mothers of all of the infants enrolled in the study to ensure that the children received high-quality medical and emergency care during the study period.
For the first time, we have taken a vaccine from the earliest discovery through every stage of development. This major contribution to public health is thanks to the knowledge and dedication of our national researchers, and I am proud and humbled to have been a part of this unique collaboration.